| abstract |
Disclosed are oral pharmaceutical compositions, kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein Compound (1), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable sa lt thereof, is administered in a selected dosage range: Formula (1) Also disclosed are the use of a compound of formula (1), or a pharmaceutically acceptable salt thereof, as a control substance for validating an HCV replication assay and also as a control substance for determining the relati ve effectiveness of one or more substances, alone or in combination, to inhibit the replication of HCV. |